NCT02631746 - Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

July 31, 2019

Conditions

Acute Adult T-Cell Leukemia/LymphomaAdult T-Cell Leukemia/LymphomaChronic Adult T-Cell Leukemia/LymphomaHTLV-1 InfectionLymphomatous Adult T-Cell Leukemia/LymphomaSmoldering Adult T-Cell Leukemia/Lymphoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

OTHER

Pharmacogenomic Study

Correlative studies

Trial Locations (6)

10461

Montefiore Medical Center-Einstein Campus, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

20892

National Institutes of Health Clinical Center, Bethesda

NCI - Center for Cancer Research, Bethesda

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH